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Abstract 
Human group IIA phospholipase A2 (hGIIA) promotes inflammation in immune-mediated 
pathologies by regulating the arachidonic acid pathway through both catalysis-dependent and 
-independent mechanisms. The hGIIA crystal structure, both alone and inhibitor-bound, 
together with structures of closely related snake-venom-derived secreted phospholipase 
enzymes has been well described. However, differentiation of biological and non-biological 
contacts and the relevance of structures determined from snake venom enzymes to human 
enzymes are not clear.  We employed molecular dynamics (MD) and docking approaches to 
understand the binding of inhibitors that selectively or non-selectively block the catalysis-
independent mechanism of hGIIA. Our results indicate that hGIIA behaves as a monomer in 
the solution environment rather than a dimer arrangement that is in the asymmetric unit of 
some crystal structures. The binding mode of a non-selective inhibitor, KH064, was validated 
by a combination of the experimental electron density and MD simulations. The binding 
mode of the selective pentapeptide inhibitor FLSYK to hGIIA was stipulated to be different 
to that of the snake venom phospholipases A2 of Daboia russelli pulchella (svPLA2). Our 
data suggest the application of molecular dynamics approaches to crystal structure data is 
beneficial in evaluating the robustness of conclusions drawn based on crystal structure data 
alone. 
Introduction 
Secreted phospholipases A2 (sPLA2s) are members of a superfamily of esterases that catalyze 
the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids to release free 
fatty acids such as arachidonic acid, and lysophospholipids. These are relatively small 
proteins and have a low molecular weight, ranging from 13 to 19 kDa and possess at least 6 
highly conserved disulfide bonds, a catalytic dyad featuring His and Asp residues and a 
calcium binding loop (Xxx-Cys-Gly-Xxx-Gly-Gly).1 In order for sPLA2s to access their 
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cellular substrate, they must firstly interact with the phospholipid bilayer using a functional 
binding site called an interfacial binding face which is composed of N-terminal α-helical 
residues and other hydrophobic residues in proximity that together form a relatively planar 
surface (Fig. 1)2,3. These residues also form an opening where a single phospholipid molecule 
can enter and penetrate through to the active site cavity where the catalytic dyad is present  
Human group IIA (hGIIA, Uniprot accession code P14555), was among the first mammalian 
subtypes of sPLA2 characterized. It was originally purified from the synovial fluid of patients 
with rheumatoid arthritis.4-7 Due to the ability of these enzymes to provide substrates to 
cyclooxygenases (COXs) and lipooxygenases (LOXs) in the arachidonic acid pathway, 
hGIIA is implicated in pathology of specific diseases with an inflammatory component. 
Although the overall activity of hGIIA in healthy individuals is relatively low and confined to 
glandular secretions, in inflammatory diseases such as rheumatoid arthritis8, acute coronary 
syndrome,9,10 sepsis,11 cancer,12,13 acute pancreatitis14 and asthma,15 marked induction of the 
enzyme in the plasma is observed, which is also correlated with the disease severity. In the 
case of rheumatoid arthritis, its concentration in plasma can rise up to 8-fold over normal.16 
Snake venom sPLA2s, on the other hand, can exert more diverse physiological effects than 
the mammalian sPLA2 types, including neurotoxicity, myotoxicity, cardiotoxicity, platelet 
aggregation and anticoagulant effects, in spite of having a high amino acid sequence identity 
in comparisons that range from 30 to 60% to hGIIA.17,18 In the case of sPLA2 purified from 
the venom of Daboia russelli pulchella (VRV-PL-VIIIa, svPLA2, Uniprot accession code 
P59071), a 49% identity to hGIIA is seen (Fig. S1). 
In comparison with other human sPLA2 subgroups, such as Group V and Group X, or other 
mammalian group IIA sPLA2s, hGIIA exhibits lower catalytic activity towards the 
zwitterionic phosphotatidylcholine (PC) bilayer substrates.19-21 The origin of this would 
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appear to be associated with the unusually large number of basic residues, giving more 
selectivity towards anionic charged glycerophospholipids.1 It is also partially explained by 
the absence of a tryptophan residue on the interfacial binding surface that is present in a 
subset of snake venom sPLA2s, such as Trp20 in the Naja Naja venoms (Uniprot accession 
code P15445) or other subgroups of human sPLA2, such as found in the group V (Uniprot 
accession code P39877) as Trp30. The amphiphilic indole moiety of the tryptophan would 
promote the penetration of the enzyme into the lipid interface of the phospholipid bilayer, 
thereby allowing the access of the substrate into the catalytic active site. In fact, the V3W 
mutation introduced into hGIIA enhanced the activity towards unilamellar PC vesicles by 
over 250-fold.22 Furthermore, in a study using the H47Q mutant of hGIIA, which only 
exhibits 1% of the residual catalytic activity compared to the native enzyme, it was 
demonstrated that it retained its ability to promote prostaglandin E2 (PGE2) production and 
COX-2 expression in fibroblast-like synoviocytes (FLS) obtained from patients with 
rheumatoid arthritis, in the presence of tumor necrosis factor α (TNFα).23 Taken together, 
these observations suggest that the catalytic activity of hGIIA alone does not sufficiently 
explain its role in the inflammatory pathway. hGIIA has an ability to activate several 
signaling pathways through direct interaction with another protein and a few candidates  such 
as heparin sulfate proteoglycan (HSPG),24-26 integrins αvβ3, α4β1 and α5β127,28 and 
vimentin29 have been suggested as binding partners. Similarly for the snake venom sPLA2s, it 
is suggested that while the catalytic activity is mainly responsible for the digestion of lipids in 
prey, other toxicological effects have been attributed to the interaction with another protein 
target via a separate binding site distinct from the substrate binding site.18,30 
It has previously been demonstrated that the catalysis-dependent and -independent actions of 
hGIIA are pharmacologically distinguishable and that cyclic analogues of the pentapeptide 
FLSYK (Phe-Leu-Ser-Tyr-Lys) were identified to be a unique class of inhibitors that 
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selectively block the interaction between hGIIA and vimentin.29 This results in the inhibition 
of PGE2 production, whilst being only a very weak inhibitor of diheptanoyl PC (DHPC) 
hydrolysis. Interestingly FLSYK is an endogenous sequence, originally found from the 
tryptic digestion of the hGIIA itself.31 From molecular docking studies, which predicted a 
close association between the N- and C-termini of the pentapeptide upon binding to hGIIA, 
cyclic pentapeptide analogues of the FLSYK, including cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2), 
were developed which had improved the inhibitory potency by 5 to 50 fold and this 
enhancement in the potency of inhibition of hydrolysis can be explained by the increased 
affinity to hGIIA.32 These observations are also consistent with the increased inhibitory 
action on PGE2 release from fibroblast-like synoviocytes (FLS), which results from 
prevention of the interaction between hGIIA and vimentin.29 
Currently there are two X-ray crystal structures of the complex of sPLA2 and the FLSYK 
inhibitor,33,34 which in both cases are the svPLA2 subtype of the protein. The overall 
conformation of FLSYK in the two crystal structures and data from computational 
modelling32 are in conflict, and provide no consistent model of FLSYK binding to hGIIA.  
Importantly, there are two X-ray crystal structures of hGIIA in complex with KH064 ((S)-5-
(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoilamino)-Pentanoic acid, KH064),35 an inhibitor 
that blocks both the catalysis-dependent and -independent action of hGIIA,29 but they show 
differences in conformations. A series of molecular dynamics (MD) simulations studies have 
been performed to understand the structure and binding of the ligands to svPLA2 and hGIIA. 
The aim is to resolve the apparent inconsistencies in the binding of ligand in hGIIA and 
svPLA2. 
Methods 
Preparation of molecules and parameters 
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The initial structures of hGIIA complexed with the ligand KH064 were taken from the PDB 
entries 1J1A35 and 3U8H.29 The crystal structure 1J1A has two alternate binding modes of 
KH064 that occur in a 50:50 occupancy ratio, while 3U8H only has a single binding mode 
differing from the other two. Each of these three binding modes of KH064 was independently 
subjected to MD simulations and analysis. The topologies of the ligand molecules KH064 
were generated using the ‘Automated Topology Builder’ (ATB) and are available from the 
ATB repository version 2.2 (https://atb.uq.edu.au).36  
The ligand-free hGIIA was prepared from 3U8I,29 which was chosen as it has been 
determined at 1.1 Å resolution, the highest of all hGIIA structures available at the PDB. 
However, as 3U8I has the inhibitor p-bromophenacyl bromide (BPB) covalently bound to the 
His47, in order to prepare the native ligand-free protein this non-standard residue was 
modified to the native standard histidine residue, and the inhibitor eliminated. 
The svPLA2:FLSYK used in the study was the 1JQ9
33 structure, which at 1.8 Å is the highest 
resolution. The FLSYK inhibitor used in the study was prepared as a non-modified peptide 
with charges allocated at the physiological pH. For initial positioning of the FLSYK ligand in 
hGIIA, hGIIA structure was superimposed on the svPLA2:FLSYK complex using the pair_fit 
function of PyMol 1.6 (Schrödinger, LLC), so that the relative position of the ligand to the 
protein is transferred to hGIIA after removal of the svPLA2 structure. 
The MD simulations in a solution environment were performed in a truncated octahedral box 
with ~23500 simple point charge (SPC) water molecules.37 The configuration of the solvent 
was relaxed by performing a steepest descent minimization. The system was then further 
equilibrated by performing a 200 ps MD simulation, with the heavy atoms of the protein 
positionally restrained, before a series of unrestrained MD simulations were commenced. 
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The simulation of 1J1A and 3U8H in their crystal environment was performed by creating 
crystal unit cell models. The crystal structures 1J1A and 3U8H are isomorphous in the P31 
space group and contain two protein molecules, each with a single KH064 molecule, in the 
asymmetric unit. A unit cell comprises three asymmetric units, which includes a total of 6 
protein chains and 6 ligands. A unit cell for 1J1A (both binding modes) and 3U8H structure 
was constructed using the CCP4 program.38 All component molecules as deposited in the 
PDB file including the crystal solvent (water) and Ca2+ ions were used in crystal MD 
simulations. The crystal solvent contents were 55.0% for 1J1A and 57.5% for 3U8H. Sodium 
and chloride ions were added and provided an overall neutral charge using the default 
protocol. This process added 10 sodium and 142 chloride ions into each unit cell of both 
binding modes of 1J1A, while for the unit cell of 3U8H structure 10 sodium and 130 chloride 
ions were added. Crystal unit cells were simulated under a triclinic periodic boundary 
condition. 
Molecular dynamics 
All MD simulations were performed using the GROMOS11 simulation package39,40 in 
conjunction with the GROMOS 54A7 force field.41 All the simulations were performed at 
constant temperature (298 K) and pressure (1 atm). This was achieved using a Berendsen 
thermostat with a coupling time of 0.1 ps and a Berendsen barostat with a coupling time of 
0.5 ps.42 The isothermal compressibility was set to 4.575 × 10-4 kJ/mol/nm3. Non-bonded 
interactions were calculated using a twin-range cutoff. Interactions within the short-range 
cutoff of 0.8 nm were updated every time step. Interactions within the longer-range cutoff of 
1.4 nm were updated every 5 time steps together with the pairlist. To correct for the 
truncation of electrostatic interactions beyond the 1.4 nm long-range cutoff a reaction field 
correction was applied using an effective dielectric (ε) of 61. The equations of motion were 
integrated using the leapfrog scheme with a 2 fs time step. Initial velocities at a given 
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temperature were taken from a Maxwell-Boltzmann distribution. The lengths of all bonds 
were constrained to ideal values using the SHAKE algorithm with a geometric tolerance of 
0.0001.43 The list of MD simulations performed is summarized in Table 1. 
Docking studies 
Docking was conducted with Glide as part of the Schrödinger Maestro software suite 10.2. 
Chain A of the hGIIA X-ray crystal structure 3U8H was imported and all hetero atoms that 
are not part of the polypeptide other than the two calcium ions were removed. Using the 
Protein Preparation module, the protein was assigned with hydrogens, charges and correct 
bond orders. Missing atoms on Arg123 residues were automatically built and for residues 
with alternate positions, only the positions with higher average occupancy were used. The 
grid was generated at the centroid of the protein, with the size of 36 Å × 36 Å × 36 Å, which 
encompasses the surface of the binding area near the N-terminus. FLSYK and KH064 ligand 
structures were processed by the Ligand Preparation module as per default settings under the 
OPLS 2005 force field, except ligands were ionized by generating possible states at pH 7.4 
using Epik. The generated ligands were docked with Glide extra precision setting (XP mode) 
also using the flexible ligand option to allow for all possible torsional variations.  
Data analysis 
The coordinates, structure factors and electron density maps for 1J1A and 3U8H were 
obtained from the PDB and EDS (electron density server; http://eds.bmc.uu.se/eds) and the 
atom replacement of KH064 in all three binding modes were examined from difference 
density maps (2Fo-Fc and Fo-Fc) using PyMOL (Schrödinger, LLC). PyMOL was also used 
for other calculations such as the distance between atomic coordinates and the centroid of a 
set of atoms. 
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The 'Protein interfaces, surfaces and assemblies' service at the European Bioinformatics 
Institute (PISA, http://www.ebi.ac.uk/pdbe/prot_int/pistart.html)44 was used for analyzing the 
interfaces between protein chains with another protein chain, a ligand or a protein chain and a 
ligand. The area of interfaces involved, the solvation free energy gain and the residues 
involved the formation of interface were determined in the analysis. The MolProbity server 
(http://molprobity.biochem.duke.edu/index.php)45 was used to assess the quality of protein 
and peptide structures by inspecting the overall clash score, Ramachandran plot,  rotamers, 
bond angles and bond lengths. 
All MD trajectories were analysed using the Gromos++ set of programs. The backbone root 
mean square positional deviation (RMSD) of residues within well-defined regions of 
secondary structure (α-helices and β-sheets) between all possible pairs of structures were 
determined. The time series of torsional dihedral angles for all 3 rotatable bonds of KH064 
molecule (-Ar-O-; -O-CH2-, -CH2-Ar-) were calculated across the trajectories. 
Results 
Validation of hGIIA:KH064 complex structures 
The atom placement and electron densities of all three binding modes of KH064 in hGIIA 
crystal structures were analyzed and compared. From the inspection of differential electron 
density maps, it is clear that in both conformers of 1J1A that the atoms are less appropriately 
placed in comparison to 3U8H, and particularly around the benzyl ether moiety, as clearly 
displayed in the Fo-Fc map (Fig. 2). 
In all three binding modes in the crystal structures, there are two chains of the protein in close 
contact with each other on the interfacial binding face of the protein, where substrates access 
and enter the active site (Fig. 3 A, D, G). This forms part of the larger interface between the 
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two protein chains in the asymmetric unit deposited in the PDB. After 1 ns of MD 
simulations in the solution environment, the separation of the monomer chains is observed in 
all these calculations, with minimal contact between them (Fig. 3 B, C, E, F, H, I). In case of 
the two binding modes of 1J1A, complete separation of monomer chains occurs. In the MD 
runs of 3U8H, the monomer chains are held in close proximity only by the weak π-stacking 
force between the phenyl rings of each of KH064 ligand, which was not seen for 1J1A, while 
there were no interactions between the macromolecule chains. When compared to the results 
of MD simulations in the crystal environment, this suggests that the apparent dimer structure 
of the asymmetric unit in the crystal structure and its interface is stabilized only by the crystal 
packing forces. The KH064 ligand remained within the N-terminal binding site of the protein 
throughout in all six simulations although it displayed high flexibility. 
For the MD simulations on all three binding modes of KH064 to hGIIA in the crystal 
environment, the conformation found in 3U8D displayed evidence for less fluctuation in 
comparison to both KH064 structures of 1J1A. This is consistent with the RMSD of the six 
KH064 ligands in a unit cell, as the RMSD plot shows that the conformation of KH064 
ligands in 3U8H were remained more persistent and formed a more steady plateau state in 
comparison to the other two (Fig. S2). The difference in structural fluctuations is most 
pronounced in the analysis of the dihedral angle between CH2 and the aromatic ring of the 
ligand (Fig. 4). In the crystal structure, the dihedral angle around -CH2-Ar- (of the benzyl 
ether group) of the ligand is -90° for the first binding mode of 1J1A, 165° for the second 
binding mode of 1J1A and -100° for 3U8H. While both 1J1A ligand conformations 
demonstrate fluctuations of the dihedral angle right through -180° to 180° over the course of 
MD simulations, the dihedral angle in 3U8H remains relatively steady around -100° with 
significantly fewer fluctuations. The analysis of RMSD and dihedral angles data together are 
convincing that the ligand conformation found in 3U8H is relatively more stable than the 
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other two structures. Although the different position of the benzyl ether group of the KH064 
ligand displayed a significantly different level of fluctuations of the dihedral angle 
around -CH2-Ar- between the three binding modes, it is notable that the phenyl heptadyl 
group occupies the same region of the protein in all three binding modes. This region is 
adjacent to the N-terminal α-helix, at the entrance leading to the active site. 
Prediction of stoichiometry of ligand-free hGIIA in a solution environment 
Both chains of ligand-free hGIIA prepared from 3U8I were subjected to MD simulations in 
the solution environment, which was conducted in duplicate runs. At time 0 (Fig. 5 A), which 
represents the protein conformation of the X-ray crystal structure, the two protein chains 
form a dimeric interface between 15 residues of each chain, namely Asn1-Val3, His6, Arg7, 
Lys10, Glu16, Ala18, Leu19, Phe23, Val30, Lys62, Phe63, Tyr111 and Ser113, with a size of 
582.8 Å2, which represents a gain in solvation free energy of -13.8 kcal/mol. Within 1 ns of 
the MD simulation, the two chains of the proteins were starting to separate and by 10 ns of 
the simulation, each chain was completely divorced from the other in both MD runs (Fig. 5 B 
and C). This is also consistent with the results from the MD simulation of the hGIIA:KH064 
dimeric complex described above. In the presence of the KH064 ligand, the two chains were 
held only weakly by the π-stacking forces of the KH064 ligand, but in this simulation, 
complete separation was observed. The formation of the dimeric interface observed in the 
crystal structure, although energetically favorable with a negative solvation free energy value, 
seems to be a phenomenon that only occurs in this crystal environment and is also 
unfavorable in the solution environment. 
Binding of FLSYK pentapeptide in hGIIA and svPLA2 
In the crystal structure of FLSYK-bound svPLA2 1JQ9, the ligand FLSYK directly interacts 
with the chain A of the protein by forming an interface area of 542.7 Å2 with a gain in 
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solvation free energy of -6.7 kcal/mol while having minimal interactions with chain B of the 
protein. MD simulation calculations were performed in parallel for both the complexes of the 
svPLA2 dimer (chain A and B):FLSYK and the svPLA2 monomer (chain A):FLSYK in the 
solution environment. The dimer:FLSYK MD simulation revealed that the stability of the 
dimeric structure is retained in the solution environment as shown in the minimal changes of 
the backbone RMSD (see Fig. S3, and also Fig. S4 for RMSF plots). However, the ligand 
FLSYK, adopted alternate conformations and novel interactions with chain B of the protein 
(Fig. 6). There was no global conformational change of the protein in either of the runs of 
MD simulation of the monomer:FLSYK complex, as the backbone RMSD remained within a 
range of 0.2 to 0.4 nm (Fig. S5). In the monomer:FLSYK MD simulation the ligand migrated 
away from the known binding site at the entrance to the active site and adopted alternative 
conformations as seen in the large RMSD of the backbone of the FLSYK attaining over 0.8 
nm (Fig. 7 A). Further analysis confirms that the ligand is no longer occupying the binding 
site at the time when the large RMSD is observed. In the other run, the FLSYK stayed within 
the binding site, and the RMSD remained within the 0.2 to 0.5 nm range over throughout the 
first 20 ns of the simulation. 
We performed an MD simulation to examine the interaction of the both the hGIIA monomer 
and dimer structures and FLSYK. In both of the hGIIA dimer:FLSYK complex simulations 
performed, the chain B was completely separated from chain A after 1 ns (Fig. S6), and 
therefore it was decided only a further test of the hGIIA monomer:FLSYK complex was 
required. The hGIIA monomer:FLSYK complex was found to be highly unstable, as 
supported by the large RMSD in both runs of MD simulations, reaching over 2 nm in one of 
the runs (Fig. S7). The orientation of FLSYK in 1JQ9 cannot be maintained as might be 
predicted from a simple superimposition with the hGIIA structure. When the hGIIA structure 
is simply overlaid with the chain A of 1JQ9, the FLSYK ligand had a steric hindrance with 
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hGIIA at His6 (Fig. S8), and therefore it was considered necessary to relax the 
macromolecule before we could proceed with MD simulation. The results indicate that the 
binding mode of FLSYK to the monomeric hGIIA is significantly different from that to the 
monomeric svPLA2, and therefore 1JQ9 does not provide any useful model of how the 
FLSYK binds in a hGIIA:FLSYK complex, any more than that the binding would be at or 
near the active site entrance. 
Docking ligands to the hGIIA structure 
In order to further consider the requirements of FLSYK binding to hGIIA, docking of the 
KH064 ligand on the chain A of 3U8H structure with Glide was performed. A total of four 
poses were generated, which are of high similarity to the conformation of KH064 found in 
the X-ray crystal structure 3U8H (Fig. S9). The RMSD of the docked ligands in comparison 
to the KH064 found in the 3U8H structure ranged from 1.5 to 1.7 Å across all four results. 
Although the positions of the phenyl groups and the dihedral angles of the carbon chains are 
not identical to those in the crystal structures, overall the contacts the ligand make to the 
surrounding hydrophobic groups and the formation hydrogen bonds are reproduced by the 
docking simulation to a high level of similarity.  
In the docking of FLSYK to the chain A of 3U8H, the top six poses had docking scores less 
than -9.0. These were of -9.93, -9.80, -9.69, -9.62, -9.55 and -9.35, where the increasing 
negativity indicates more favorable interaction in the docking calculations. The top six 
docking poses display the ligands occupying a similar region of the protein within the 
N-terminal binding site, but are significantly different to the region FLSYK binds to on 
svPLA2 in the 1JQ9 X-ray crystal structure (Fig. 8). The RMSDs of the second to sixth 
scoring conformations in comparison to the top scoring pose are 2.2, 1.5, 1.6, 2.1 and 2.2 Å 
respectively, and 1.6, 1.0, 1.3, 1.8 and 1.5 Å respectively, when backbone atoms only were 
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considered. In all six results, the leucine sidechain of the ligand formed hydrophobic 
interactions with the surrounding Leu2 Phe5 and Val30 residues of hGIIA while hydrogen 
bonds formed were between one of the hydrogen atoms of the N-terminal amino group of the 
ligand and the Nδ1 atom of His47, and the backbone oxygen atom in the phenylalanine of the 
ligand and the hydrogen on the backbone nitrogen of Gly29. 
Discussion 
X-ray crystallography remains an indispensable tool in the structural biology, and especially 
for deciphering how a ligand binds to its target protein. However, the accuracy and utility of 
structural information that can be deduced from the X-ray crystallography depends on 
multiple factors including, most evidently, the resolution. The general limitations in the 
descriptions of the binding mode, orientation and conformation of small non-covalently 
bound organic ligand molecules in crystallography do exist and are well-documented.46 In 
addition, it may also be difficult in some cases to observe conclusive electron density 
evidence in the supposed binding region, where it only partially exists or is minimal. In the 
extreme situation the crystallographic approval is intractable, even when some clear electron 
density exists which is unexplained by the protein atoms and solvent alone. Some relatively 
ambiguous binding conformations have been well described in the literature,47 but in general 
active sites in proteins are more ordered than elsewhere. Also, and more especially in the case 
of ligands of extended length or size, crystallography can determine there is more ordered 
binding in one region relative to another. Focused scrutiny of the ligands, and the electron 
density in the vicinity, can remove most ambiguity, though assessments of the interpretations 
are sometimes continuously made, including after deposition of coordinates has been made 
with the databank.48 The trials and tribulations of placing ligands in protein crystal structures 
have been reviewed in the literature from a number of perspectives.47,49-52 There is also 
evidence that the details of the crystal, and the manner in which the ligand is introduced can 
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affect the mode of binding, representing strong evidence that there is no complete guarantee 
that publically released structural coordinates are representative for the biologically active 
species. Very recently a report has been made that the existence of polyethylenes as 
precipitant or cryoprotectants in crystals can influence the location observed of ligands,53 and 
although there are no polyethylenes in any crystal structures used in this study, it serves as a 
reminder that variants of the protein environment could have an effect on the location of the 
ligand. We have examined the ligand binding for a number of Group IIA sPLA2:ligand 
complexes for which there are crystal structures available with high resolution (equal or less 
than 2.3 Å), for the purposes of a better understanding of the inhibitory mechanisms available 
for hGIIA. 
It has been established that hGIIA can provide a dual function, exerting its actions through 
either catalysis-dependent or -independent mechanisms.23 However, little is known about 
how the catalysis-independent mechanism relates to the structural aspects of the protein as 
only relatively subtle conformational changes have been described.29 Allosteric inhibition 
must be considered for the inhibition of the catalysis-independent action, as it may not 
involve a global conformational change of hGIIA because the catalytic machinery activity of 
the protein would need to remain unaffected. The protein very conceivably has at least two 
distinguishable ligand binding sites that each play an important role for the mechanism of 
action, or more simply the inhibition is achieved at a single binding site involving a subtle 
local conformational change, which could be the case especially for the non-selective 
inhibitors.  
In the work, we used MD to assess the stability of the structure model, for instance in the area 
of ligand binding by considering the fluctuations of the ligand. Checking the atom placement 
in the electron density is the primary method of assessing the validity of the ligand binding in 
crystallography, but MD simulations have been used as an additional structural validation 
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tool, exploring the assumption that the conformation found in the crystal structure is the most 
stable. Models with less fluctuation during the MD simulation, and less change in RMSD and 
dihedral angles occupy a more stable conformation. 
In the case of the two models of the hGIIA:KH064 complex in 1J1A, inappropriate 
placement of atoms seemed to have occurred as observed from the inspection of the electron 
density maps. To determine whether a conformation of KH064 is more favorable, structural 
validations of all the hGIIA:KH064 complexes were performed using MD simulations. The 
MD simulation results for the hGIIA:KH064 complexes indicated some fluctuation of the 
ligand in all three models tested, which was within our prior expectations since the KH064 
molecule is highly flexible. The MD did support that the KH064 ligand was more stable in 
the 3U8H simulation than the two 1J1A simulations and is evidence of the appropriateness of 
the KH064 conformation observed in the 3U8H crystal structure. However, it is possible in 
cases where multiple conformations may exist, the calculated energy from MD may be 
similar enough that there is no way to distinguish them. Limitations to MD analysis is seen in 
such cases, as it is difficult to determine whether multiple conformations exist in the 
physiological environment as multiple energy troughs may exist in the molecule, or the 
power of MD technique not being sensitive enough to determine the single lowest energy. 
Although the difference in placement of the benzyl ether group of KH064 in each of the 
hGIIA:KH064 complex structures affected the degree of the fluctuations upon MD 
simulations significantly, it was observed that the phenyl heptadyl group, which is highly 
hydrophobic, occupies the N-terminal binding site constantly in all three binding modes of 
the ligand. Table 2 displays the χ1 (C-Cα-Cβ-Cγ) dihedral angle of the His6 residue, which 
is a part of the N-terminal α-helix, of all hGIIA crystal structures available at the PDB. The 
dihedral angle is within the range of 155.7° to 168.7° for the ligand-free hGIIA structures and 
3U8H. The KH064 is an inhibitor selective for the catalytic-dependent mechanism covalently 
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bound at His47, distant from the N-terminal α-helix. All ligand-bound hGIIA crystal 
structures have the dihedral angle ranging between 55.0° and 72.2°, including the 3U8D 
structure which has a LY311727 ligand that is known to non-selectively inhibit both the 
catalysis-dependent and -independent mechanisms.29 The common feature shared in these 
crystal structures is that upon the introduction of a ligand at the N-terminal binding site at the 
entrance to the active site, a local conformational change involving the rotation of His6 
around the χ1 dihedral is induced, which subsequently causes an enlargement of the ligand 
binding site adjacent to this residue. The space created is then occupied by the hydrophobic 
or aromatic moiety of the ligand, and is within 4 Å of the Cβ atom of His6. This has been 
previously put forward as the general mechanism of action for the inhibition of the catalysis-
independent mechanism and more specifically for the interaction between hGIIA and 
vimentin.29 Although there are two non-selective inhibitors occupying this space, as found in 
structures 3U8D and 3U8H, we are yet to determine whether the other inhibitors binding to 
this pocket exhibit such non-selective inhibition. If future experiments could demonstrate that 
inhibitors selective towards catalysis-independent mechanism use their hydrophobic moiety 
to occupy this space of hGIIA, this region could be shown to be a significant feature in the 
interaction with vimentin. 
There are 16 X-ray crystal structures of hGIIA published in the PDB, of which eight consist 
of an asymmetric unit of only a single chain, six structures of two chains and two structures 
of six chains (Table 2). The protein biological unit stoichiometry of hGIIA is listed in the 
PDB as homodimer for five structures and monomer for eleven. Due to such inconsistencies, 
and no known previous systematic effort to understand the biologically active species, we 
examined features relating to functional stoichiometry and how hGIIA might exist in the 
physiological conditions by performing MD simulations in a solution environment, as an 
assembly or not. 
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We have conducted MD simulations of the KH064-bound hGIIA structures in both the 
crystal and solution environments in order to test the hypothesis that the association observed 
in the crystal structure is a consequence of the crystal packing effect only, rather than that it 
exists as a dimer in solution. In the MD simulations the dimer was stable in the crystal 
environment but the two chains separated in solution. Similarly, the two protein chains 
separated in the simulations of the ligand-free hGIIA structures in solution. Overall, our study 
shows that it is unlikely for hGIIA to exist as a dimer in a solution environment or the 
physiological conditions, although it cannot be unambiguously shown that a dimeric form of 
hGIIA cannot exist in some environments, and also conceivably in equilibrium with the 
monomer. The use of the monomeric chain alone can be implied for modelling the 
interactions of hGIIA, especially for the one that involves vimentin. The binding site of 
hGIIA where the non-selective inhibitors bind is important for the interaction with vimentin, 
as interference of this region with the inhibitor led to inhibition of the proinflammatory signal 
caused by the interaction.29 If hGIIA existed as a dimer under physiological conditions, this 
region would not have sufficient solvent exposure to allow any interaction with vimentin. 
That the biologically active unit only consists of the monomer for hGIIA in the solution 
environment is perhaps not particularly surprising, as the entrance to the active site near the 
N-terminus should be exposed to the “exterior” in order for the natural substrate to enter and 
access the catalytic site. The formation of the interface between the two protein chains 
observed in some hGIIA crystal structures would completely block the exposure of the 
entrance to the substrate. In such a dimer form the protein would be anticipated to have a 
severe handicap to the catalysis. The formation of interfaces found in several hGIIA crystal 
structures occurs between substantially different residues or areas of the protein, with 
different interface sizes (Table S1).  The dimer structures we have used for MD simulations 
(3U8H and 3U8I) have interface area with favorable solvation energy, and therefore are 
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highly represented in the experimental structures, although they became unstable upon 
simulations in solution. The crystallographic data shows the potential for many interfaces in 
the crystal forms, but a conclusion about favored interactions is not possible. 
There is no X-ray crystal structure of the complex between hGIIA and FLSYK pentapeptide 
or its analogue inhibitors. 1JQ9 represents the structure of a complex between the homodimer 
of svPLA2, a structurally similar protein to hGIIA, and the FLSYK ligand, which might be 
anticipated to serve as an excellent scaffold for modelling the binding of FLSYK to hGIIA.  
As earlier calculations established that hGIIA is most likely to exist as a monomer under the 
physiological conditions, it is reasonable to model the binding of FLSYK to the hGIIA in its 
monomeric form, rather than as a dimer. Therefore, when we then considered the potential 
for the svPLA2:FLSYK complex to be used as a model for the prediction of the 
hGIIA:FLSYK complex, only the complex of monomeric svPLA2 and FLSYK was thought 
to be relevant. However the results showed that the binding of the ligand is stabilized by the 
interface between the two chains, which implies the necessity of the second chain of svPLA2. 
That the FLSYK binding was not stable in monomeric svPLA2 in one of the MD runs (Fig. 7 
A) indicates that either FLSYK binding to monomer is not energetically favorable or svPLA2 
and hGIIA behave differently enough that they do not represent analogous situations. 
In order to pursue this further, we performed MD simulations appropriate for the study of the 
interaction of both the monomeric and dimeric hGIIA with FLSYK. Indeed, the results of the 
MD simulations of the hGIIA dimer:FLSYK complex indicate that the dimeric structure was 
completely unstable in the presence of the ligand and also the ligand was involved in 
interactions with only one chain of the protein. This clearly implied that the role of the 
FLSYK ligand in stabilizing the dimeric structure of the protein would be unique to the 
svPLA2 isotype. The results of MD simulations of the hGIIA monomer:FLSYK have 
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revealed that the 1JQ9 structure does not provide any useful foundation for a prediction of the 
binding mode of FLSYK in a hGIIA:FLSYK complex, other than that the binding would be 
at or near the active site entrance. 
Docking calculations were employed to produce models of the binding modes of FLSYK on 
a single chain of hGIIA. Docking does not guarantee to identically reproduce the ligand 
binding conformations seen in the X-ray crystal structures or the physiological conditions, 
but rather provide similar poses which are of great value. Using docking calculations on 
KH064, it was indeed possible to produce ligand placement similar to the one found in the X-
ray crystal structure 3U8H, giving an indication of the level of reproducibility possible from 
the docking calculations. We consider the docking algorithm had performed to expectations. 
There are structural differences in the N-terminal binding site between the two sPLA2s 
studied in this work, and most notably the glycine in svPLA2 and histidine in hGIIA at 
position 6 in the sequences, that are significant in preventing the ligand from binding to 
hGIIA in the same manner as to svPLA2. The docking results for FLSYK on hGIIA were 
significantly different from the FLSYK on svPLA2 in the 1JQ9 crystal structure. This is in 
agreement with the MD results for FLSYK with the hGIIA monomer, in so far as the position 
of the ligand was not as in the 1JQ9 crystal structure because of unstable binding or the 
adoption of alternative conformations. Considering that the svPLA2 dimer was stable with 
FLSYK in the simulations, the specific conformation seen in 1JQ9 may be a situation unique 
to svPLA2, and therefore not valid in the case of binding to monomer of hGIIA. 
All of the top six docked conformations of FLSYK to hGIIA have two common hydrogen 
bonds and hydrophobic contacts at the amino acids of the N-terminal side of the ligand. 
However it can be seen that the position of the atoms at the C-terminal end, such as the lysine 
sidechain, is relatively varied between the docking poses. The commonality of the 
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interactions near the N-terminal end implies the protein residues involved in these 
interactions are potentially important to the binding and therefore the mechanism of action of 
FLSYK, but also the observations of the high flexibility on the C-terminal side of the peptide 
is perhaps unsurprising for such a ligand. 
The docking studies produced models of the binding mode of FLSYK to hGIIA, and our top 
six scoring poses provide our best representation of the physiological situation. Future studies 
involving X-ray crystallography of the co-crystallization of hGIIA and pentapeptide-based 
inhibitors, which have been difficult to achieve, would provide an accurate snapshot of the 
binding mode of the ligand and understandings in what region of the protein is involved in 
the interaction with another protein.  
Conclusions 
In this work, the structural aspects of hGIIA function were investigated by studying the 
binding of varied types of ligands using MD simulations. The work has allowed clarification 
of some conflicts in the two reported crystal structures in which the inhibitor KH064 is bound 
to hGIIA. MD simulation served as an important validation tool for determining the correct 
binding mode of the ligand KH064. The limitations of experiments must be understood and 
care must be taken when considering the ligand binding modes in the coordinates obtained 
from the PDB, or the crystallographic results for important ligands are not available. A 
simple cross-check of the coordinates downloaded from PDB with the electron density data 
can demonstrate misplacement of ligand atoms despite having accurate placement of protein 
atoms because the validation criteria for ligand atoms are not as stringent to that of protein 
atoms. At the extreme the coordinates for a ligand can be chemically invalid or does not 
reflect the state found in the biological conditions.  MD simulation could be used to verify the 
validity of the ligand binding mode by assessing the degree of stability of binding. 
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The results here have consistently displayed that hGIIA is favored to exist as a monomer in 
the biological environment. Intermolecular interactions exist in the hGIIA crystal structures, 
but may only be stabilized by the total forces of crystal packing, as opposed to being true 
dimers. In the presence of KH064 ligands, the two monomer chains can be held in proximity 
by the weak π-stacking forces of the ligand in solution, but the remainder of the protein chain 
may have no significant interaction with any other.  
Our work has served to clarify aspects of the features of the hGIIA that are important for 
structure-based drug design. More importantly for inhibitors reported to have potential 
application in disease treatment, the binding of the FLSYK pentapeptide observed with 
svPLA2 in the crystal is of little specific consequence for understanding its inhibition of 
hGIIA. There is great interest in obtaining structural information on the binding of FLSYK to 
hGIIA, and until more experimental information is available we suggest this work provides 
the most likely model in which the first three amino acids (FLS) of the pentapeptide are 
suitably bound at the N-terminal binding site. Altogether, these findings clarify the structural 
basis of the mechanisms of inhibition of some hGIIA inhibitors, which could be crucial while 
targeting the interaction of hGIIA with vimentin. 
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Figure legends 
FIGURE 1 Depiction of hGIIA from PDB accession code 3U8H. Several N-terminal α-
helical residues and adjacent hydrophobic residues, labeled and in yellow, constitute the 
interfacial binding surface that promotes interaction with the aggregated phospholipids. 
These residues also form the entrance to the active site cavity where a phospholipid molecule 
can penetrate. Several hGIIA inhibitors are known to bind to this region, making interaction 
with some of these residues. Leu2, Val3 and His6 are from the N-terminal α-helix. 
FIGURE 2 The ligand found in the first binding mode of 1J1A (A), the second binding mode 
of 1J1A (B) and the binding mode in 3U8H (C) is shown in stick representation with 2Fo-Fc 
map contoured at 1 σ on the left and Fo-Fc map contoured at 2 σ on the right. The blue color 
represents the positive and the red color represents the negative and densities. The orientation 
of the phenyl heptadyl group of the ligand significantly differs between these binding modes 
and the difference electron density map displays the appropriateness of the atom placement. 
All three binding modes of KH064 from the two crystal structures, namely 1J1A binding 
mode #1 (orange), #2 (magenta) and 3U8H (cyan), are superimposed (D). The positions of 
the ligands in 1J1A binding mode #1 and #2 are identical, except for the position of the 
phenyl ring. The position of the phenyl rings and the dihedral around -CH2-Ar- of the benzyl 
ether group significantly differ between all three binding modes. 
FIGURE 3 From left to right, are the crystal structure and snapshots taken at 1 ns after the 
first MD simulation and the second simulation of hGIIA structures with KH064 ligand. Three 
crystal structures were subjected to MD simulations, namely 1J1A binding mode #1 (A-C), 
1J1A binding mode #2 (D-F) and 3U8H (G-I). The binding mode #1 and #2 refers to the 
alternative binding mode of the ligand KH064 in the crystal structure 1J1A. 
FIGURE 4 Analysis of -CH2-Ar- dihedral angle for 6 KH064 molecules in the unit cell of 
1J1A binding mode #1 (A), binding mode #2 (B) and 3U8H (C). 
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FIGURE 5 The comparison between the crystal structure (A) and snapshots at 10 ns from 
MD simulations of ligand-free hGIIA crystal structure 3U8I in duplicate runs (B and C) show 
complete separation of the two chains occurs in a solution environment. In the first 
simulation (B), the N-terminal helix displays high mobility through the flip of the adjacent 
loop between Gly14 and Tyr21. 
FIGURE 6 Snapshots at 10 ns of MD simulation of 1JQ9 with both chains of an asymmetric 
unit and a single FLSYK ligand are shown. Although the FLSYK ligand initially deeply 
buried in the binding site of the chain A in the crystal structure, it adopted alternate 
conformations and novel interactions with the chain B were formed at 10 ns of the MD 
simulation. 
FIGURE 7 Backbone RMSD of the FLSYK peptide in the 1JQ9 chain A (monomer) 
structure in duplicate MD simulations in water (A) show that the binding is not stabilized in 
MD simulation #2. The snapshot at 20 ns time point for the simulation #2 (D) display the 
FLSYK ligand adopted an alternative conformation and no longer occupies the original 
binding site. 
FIGURE 8 Conformations of FLSYK with the top six docking scores upon docking on the 
chain A of 3U8H hGIIA structure are displayed (A). The best scoring docking conformation 
of FLSYK on hGIIA (cyan) interacts with the region of the protein that is clearly different 
from the space occupied by the FLSYK ligand found in the 1JQ9 svPLA2 crystal structure 
(orange) (B). Also the overall conformations of these two ligands differ significantly. The 
best scoring docked FLSYK pose forms five hydrogen bonds denoted by yellow dashed lines 
formed between the ligand and the protein, at positions between a hydrogen of the N-
terminus and the Nδ1 of His47, the oxygen of the backbone phenyl and the hydrogen of the 
backbone nitrogen of Gly29, the oxygen of the backbone serine and  the hydrogen of the 
backbone nitrogen of Gly31, a hydrogen of the amino group of the lysine sidechain and the 
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carboxyl oxygen of Glu55 sidechain, and an oxygen of the C-terminus and a hydrogen of the 
amino group of the Lys62 sidechain. Both A and B are in similar orientation to Figure 1. 
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Table 1 List of molecular dynamics simulations conducted in the study 
PDB ID Protein Ligand Environment Run time 
Validation of hGIIA:KH064 complex structures 
1J1A Chain A and B of 
hGIIA 
KH064 
binding mode 
#1 
Solution 1 ns 
1J1A Chain A and B of 
hGIIA 
KH064 
binding mode 
#2 
Solution 1 ns 
3U8H Chain A and B of 
hGIIA 
KH064 Solution 1 ns 
1J1A Unit cell 3 
asymmetric units 
of 6 protein 
chains of hGIIA 
KH064 
binding mode 
#1 
Crystal 12 ns 
1J1A Unit cell 3 
asymmetric units 
of 6 protein 
chains of hGIIA 
KH064 
binding mode 
#2 
Crystal 12 ns 
3U8H Unit cell 3 
asymmetric units 
of 6 protein 
chains of hGIIA 
KH064 Crystal 7 ns 
Prediction of stoichiometry of ligand-free hGIIA in a solution environment 
3U8I Chain A and B of 
hGIIA, with 
ligand unbound 
His47 
None Solution 10 ns, 
duplicate runs 
Binding of FLSYK pentapeptide in hGIIA and svPLA2 
1JQ9 Chain A and B of 
svPLA2 
FLSYK Solution 20 ns, 
duplicate runs 
1JQ9 Chain A of 
svPLA2 
FLSYK Solution 20 ns, 
duplicate runs 
3U8I Chain A of 
hGIIA, with 
ligand unbound 
His47 
FLSYK Solution 20 ns, 
duplicate runs 
None None FLSYK Solution 50 ns, 
duplicate runs 
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Table 2 Selected properties relating to the structure of all PDB entries of hGIIA 
PDB Resolution 
(Å) 
R value Space 
group 
Number of 
chains in 
an 
asymmetric 
unit 
His6 
dihedral 
angle 
around χ1 
Ligand in 
the N-
terminal 
binding site 
Hydrophobi
c group of 
the ligand 
within 4 Å of 
Cβ of His6 
1AYP 2.57 0.214 
observed 
P21 6 55.0 Yes Yes 
1BBC 2.2 0.178 
observed 
P21 1 168.7 No N/A 
1DB4 2.2 0.256 free 
0.226 work 
P6122 1 67.2 Yes Yes 
1DB5 2.8 0.240 free 
0.196 work 
P6122 1 70.4 Yes Yes 
1DC
Y 
2.7 0.269 free 
0.218 work 
P6122 1 68.3 Yes Yes 
1J1A 2.2 0.258 free 
0.227 work 
P31 2 72.2 Yes Yes 
1KQ
U 
2.1 0.240 free 
0.209 work 
P6122 1 70.2 Yes Yes 
1KV
O 
2.0 0.273 free 
0.201 work 
P21 6 69.4 Yes Yes 
1N28 1.5 0.207 free 
0.184 work 
C2 2 160.2 No N/A 
1N29 2.6 0.320 free 
0.242 work 
P6122 1 159.8 No N/A 
1POD 2.1 0.193 
observed 
P6122 1 155.7 No N/A 
1POE 2.1 0.196 
observed 
P43212 2 74.3 Yes Yes 
3U8B 2.3 0.257 free 
0.207 work 
P6122 1 161.7 No N/A 
3U8D 1.8 0.189 free 
0.121 work 
P3121 2 71.6 Yes Yes 
3U8H 2.3 0.225 free 
0.192 work 
P31 2 70.6 Yes Yes 
3U8I 1.1 0.196 free 
0.164 work 
P41 2 164.2 No, but p-
bromophena
cyl bromide 
irreversibly 
bound at 
His47 
N/A 
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FIGURE 1 Depiction of hGIIA from PDB accession code 3U8H. Several N-terminal α-helical residues and 
adjacent hydrophobic residues, labeled and in yellow, constitute the interfacial binding surface that 
promotes interaction with the aggregated phospholipids. These residues also form the entrance to the active 
site cavity where a phospholipid molecule can penetrate. Several hGIIA inhibitors are known to bind to this 
region, making interaction with some of these residues. Leu2, Val3 and His6 are from the N-terminal α-
helix.  
Fig. 1  
101x101mm (300 x 300 DPI)  
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The ligand found in the first binding mode of 1J1A (A), the second binding mode of 1J1A (B) and the binding 
mode in 3U8H (C) is shown in stick representation with 2Fo-Fc map contoured at 1 σ on the left and Fo-Fc 
map contoured at 2 σ on the right. The blue color represents the positive and the red color represents the 
negative and densities. The orientation of the phenyl heptadyl group of the ligand significantly differs 
between these binding modes and the difference electron density map displays the appropriateness of the 
atom placement. All three binding modes of KH064 from the two crystal structures, namely 1J1A binding 
mode #1 (orange), #2 (magenta) and 3U8H (cyan), are superimposed (D). The positions of the ligands in 
1J1A binding mode #1 and #2 are identical, except for the position of the phenyl ring. The position of the 
phenyl rings and the dihedral around -CH2-Ar- of the benzyl ether group significantly differ between all 
three binding modes.  
Fig. 2  
120x189mm (300 x 300 DPI)  
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FIGURE 3 From left to right, are the crystal structure and snapshots taken at 1 ns after the first MD 
simulation and the second simulation of hGIIA structures with KH064 ligand. Three crystal structures were 
subjected to MD simulations, namely 1J1A binding mode #1 (A-C), 1J1A binding mode #2 (D-F) and 3U8H 
(G-I). The binding mode #1 and #2 refers to the alternative binding mode of the ligand KH064 in the crystal 
structure 1J1A.  
Fig. 3  
177x230mm (300 x 300 DPI)  
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FIGURE 4 Analysis of -CH2-Ar- dihedral angle for 6 KH064 molecules in the unit cell of 1J1A binding mode 
#1 (A), binding mode #2 (B) and 3U8H (C).  
Fig. 4  
189x413mm (600 x 600 DPI)  
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FIGURE 5 The comparison between the crystal structure (A) and snapshots at 10 ns from MD simulations of 
ligand-free hGIIA crystal structure 3U8I in duplicate runs (B and C) show complete separation of the two 
chains occurs in a solution environment. In the first simulation (B), the N-terminal helix displays high 
mobility through the flip of the adjacent loop between Gly14 and Tyr21.  
Fig. 5  
254x175mm (300 x 300 DPI)  
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FIGURE 6 Snapshots at 10 ns of MD simulation of 1JQ9 with both chains of an asymmetric unit and a single 
FLSYK ligand are shown. Although the FLSYK ligand initially deeply buried in the binding site of the chain A 
in the crystal structure, it adopted alternate conformations and novel interactions with the chain B were 
formed at 10 ns of the MD simulation.  
Fig. 6  
254x84mm (300 x 300 DPI)  
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FIGURE 7 Backbone RMSD of the FLSYK peptide in the 1JQ9 chain A (monomer) structure in duplicate MD 
simulations in water (A) show that the binding is not stabilized in MD simulation #2. The snapshot at 20 ns 
time point for the simulation #2 (D) display the FLSYK ligand adopted an alternative conformation and no 
longer occupies the original binding site.  
Fig. 7  
254x189mm (300 x 300 DPI)  
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Caption : FIGURE 8 Conformations of FLSYK with the top six docking scores upon docking on the chain A of 
3U8H hGIIA structure are displayed (A). The best scoring docking conformation of FLSYK on hGIIA (cyan) 
interacts with the region of the protein that is clearly different from the space occupied by the FLSYK ligand 
found in the 1JQ9 svPLA2 crystal structure (orange) (B). Also the overall conformations of these two ligands 
differ significantly. The best scoring docked FLSYK pose forms five hydrogen bonds denoted by yellow 
dashed lines formed between the ligand and the protein, at positions between a hydrogen of the N-terminus 
and the Nδ1 of His47, the oxygen of the backbone phenyl and the hydrogen of the backbone nitrogen of 
Gly29, the oxygen of the backbone serine and the hydrogen of the backbone nitrogen of Gly31, a hydrogen 
of the amino group of the lysine sidechain and the carboxyl oxygen of Glu55 sidechain, and an oxygen of the 
C-terminus and a hydrogen of the amino group of the Lys62 sidechain. Both A and B are in similar 
orientation to Figure 1.  
Fig. 8  
119x144mm (300 x 300 DPI)  
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